[Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease].

Abstract

Objective: To study the clinical effect of probiotics in the treatment of non-alcoholic fatty liver disease (NAFLD). Methods: A total of 200 patients with NAFLD were randomly divided into 4 groups: control group (routine treatment group) and combined treatment group A, B and C. Each group had equal patients. The control group received orally polyene phosphatidylcholine capsules; whereas combined group A, B and C were given orally the live "combined Bifidobacterium Lactobacillus and Enterococcus powder" , "two live combined Bacillus subtilis and Enterococcus" , and the both probiotics respectively. The duration of treatment was 1 month. Laboratory parameters were evaluated before treatment and thirtieth day after treatment, including cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol(LDL-C), alanine aminotransferase(ALT), aspartate aminotransferase (AST), fasting blood glucose (FPG), serum high molecular weight adiponectin (HMW-APN) and serum TNFα. Meanwhile the faece sample was collected for routine test and bacterial culture. Liver ultrasound scan was done in all patients. Results: In terms of blood lipids and blood glucose, each group improved after treatment with significant differences (P<0.05) except for HDL-C. As for liver function, serum ALT and AST decreased after treatment in each group; especially in combined group C which were lower than those of control group [(33.7±7.6) U/L vs. (45.0±8.5) U/L; (22.0±1.6) U/L vs. (29.4±3.7) U/L; P<0.05]. TNFα levels decreased after treatment in each group, in addition the values in combined group C was significantly lower than that of control group[(0.51±0.27) µg/L vs. (0.82±0.28) µg/L, P<0.05]. Serum HMW-APN increased after treatment in each group, and the HMW-APN in combined C group was significantly higher than that of control group[(9.28±3.72) µg/L vs. (7.87±3.96)µg/L, P<0.05]. (5) After treatment, all groups showed improvement of fatty liver by ultrasound, but the difference between groups was not statistically significant. (6) Compared with before treatment, fecal flora in combined groups was all reduced (P<0.01), but it was comparable before and after treatment in control group. Conclusions: Probiotics improve intestinal microecological system in NAFLD patients via inhibiting TNFα and enhancing adiponectin, possibly resulting in regulating blood glucose, lipid metabolism, and protecting liver injury from NAFLD.

• Authors: W Wang, L P Shi, L Shi, L Xu
• Journal: Zhonghua nei ke za zhi (Zhonghua Nei Ke Za Zhi) Vol. 57 Issue 2 Pg. 101-106 (Feb 01 2018) ISSN: 0578-1426 [Print] China
• PMID: 29397594 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• ADIPOQ protein, human
• Adiponectin
• Blood Glucose
• Cholesterol, LDL
• Lipids
• TNF protein, human
• Triglycerides
• Tumor Necrosis Factor-alpha
• Cholesterol
• Aspartate Aminotransferases
• Alanine Transaminase

Topics

• Adiponectin
• Alanine Transaminase (blood, drug effects)
• Aspartate Aminotransferases (blood, drug effects)
• Blood Glucose
• Cholesterol (blood)
• Cholesterol, LDL (drug effects, metabolism)
• Humans
• Lipid Metabolism
• Lipids
• Non-alcoholic Fatty Liver Disease (metabolism, therapy)
• Probiotics (therapeutic use)
• Triglycerides (blood, metabolism)
• Tumor Necrosis Factor-alpha